期刊文献+

SWE-Emax与乳腺癌分子分型及远期预后的关系研究 被引量:5

Correlation between SWE-Emax and molecular typing as well as long-term prognosis of patients with breast cancer
下载PDF
导出
摘要 目的探讨剪切波弹性成像最大弹性(SWE-Emax)值对乳腺癌分子分型及远期预后的关系,为后续预后评估及治疗方案制定提供更多依据。方法选取2014年7月至2018年7月收治的乳腺癌患者80例,术前采用SWE检查86个病灶,分析SWE-Emax与肿物直径、组织分级、免疫组化指标及分子亚型间相关性,同时采用多因素回归分析法评价SWE-Emax可能影响因素。结果乳腺癌患者肿物直径与SWE-Emax值呈正相关(P<0.05);HER-2阳性和Ki-67阳性乳腺癌患者肿块SWE-Emax值均显著大于阴性者(P<0.05);单因素方差分析显示不同分子亚型乳腺癌患者间肿物SWE-Emax值差异有显著性(P<0.05);多元线性回归方程代入肿物直径、HER-2阳性、Ki-67阳性及分子亚型,提示肿物直径和HER-2阳性表达是影响乳腺癌患者肿块SWE-Emax值重要因素,且肿物直径影响最大(P<0.05)。结论乳腺癌患者肿物SWE-Emax值与HER-2、Ki-67表达具有相关性,临床预后差分子亚型乳腺癌患者肿物SWE-Emax值较高;SWE可在一定程度上为乳腺癌患者临床预后评价及治疗方案制定提供依据。 Objective To investigate the correlation between SWE-Emax and molecular typing as well as long-term prognosis of patients with breast cancer,so as to provide more evidence for prognosis assessment and treatment plan formulation.Methods Eighty patients with breast cancer who were admitted and treated in our hospital from July 2014 to July 2018 were enrolled in the study,whose 86 lesions were examined by SWE before operation.The correlation between SWE-Emax and tumor diameter,tissue grade,immunohistochemical indexes as well as molecular subtype was analyzed,meanwhile,the possible influencing factors of SWE-Emax were evaluated by multivariate regression analysis.Results The diameter of tumor was positively correlated with SWE-Emax value in patients with breast cancer patients(P<0.05).The SWE-Emax values in breast cancer patients with positive HER-2 and positive Ki-67 were significantly higher than those of patients with negative ones(P<0.05).Univariate analysis of variance showed that there were significant differences in SWE-Emax values among the breast cancer patients with different molecular subtypes(P<0.05).The multivariate linear regression equation and multivariate linear regression equation showed that lesion diameter,positive expressions of HER-2 and Ki-67,and molecular subtypes of breast cancer were the important factors affecting the SWE-Emax values in patients with breast cancer,and the influencing effects of the lesion diameter of breast cancer were the greatest(P<0.05).Conclusion The SWE-Emax values of tumor in patients with breast cancer are correlated with the expression levels of HER-2 and Ki-67,and the SWE-Emax values in breast cancer patients with the molecular subtypes of poor clinical prognosis are higher,therefor,SWE may provide the basis for clinical prognosis evaluation and treatment plan formulation in patients with breast cancer patients to a certain extent.
作者 李博 杜燕 王静 刘静 任雨诗 姜珏 LI Bo;DU Yan;WANG Jing(Department of Ultrasound Diagnosis,North Hospital of Xi’an City,Shaanxi,Xi’an 710000,China)
出处 《河北医药》 CAS 2020年第9期1355-1357,1361,共4页 Hebei Medical Journal
关键词 SWE Emax 乳腺癌 分子分型 预后 SWE Emax breast cancer molecular typing prognosis
  • 相关文献

参考文献2

二级参考文献22

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 5Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.
  • 6Hanna WM, Kwok K. Chromogenic in-situ hybridization:a viable ahernative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19(4) :481-487.
  • 7Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer [ J ]. J Breast Cancer, 2011, 14(4) :276-282.
  • 8Haines GK 3rd, Wiley E, Susnik B, et al. HER2 in well differentiated breast cancer: is testing necessary? [ J ]. Breast Cancer Res Treat, 2008, 112(3) :551-556.
  • 9Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer [J]. Hum Pathol, 2011,42(10) : 1499-1504.
  • 10Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer.9 A fluorescence in situ hybridization and microarray-based CGH analysis[ J]. J Pathol, 2009, 219( 1 ) : 16-24.

共引文献1213

同被引文献55

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部